Vertex Pharmaceuticals (VRTX) valuation history
Above its usual range
As of
VRTX's EV/EBITDA of 25.2x is higher than 84% of its available weekly readings from the last five years.
Share EV/EBITDA history
Chart by stockresearch.app. Reuse with credit under CC BY 4.0.
EV/EBITDA at year-end
Last weekly reading of each completed year. Rank runs from lowest (0%) to highest (100%) within the five years available on that date.
| Reading date | EV/EBITDA | 5-year rank |
|---|---|---|
| 26.3× | 95% | |
| Unavailable | Short history | |
| 23.3× | 63% | |
| 15.2× | 5% | |
| 18.1× | 15% | |
| 20.3× | 4% | |
| 60.4× | 27% | |
| 59.5× | 7% | |
| 365.9× | 83% | |
| Unavailable | Short history |
Loading related research…
About this history
- What is VRTX's current EV/EBITDA?
- VRTX's EV/EBITDA of 25.2x is higher than 84% of its available weekly readings from the last five years.
- What is VRTX's five-year median EV/EBITDA?
- The median, or middle weekly reading, is 21.4× over the last five years. Available history contains 818 weekly observations from Feb 21, 2011 to Oct 19, 2026.
- Does a low historical rank mean a stock is a buy?
- No. The rank describes a stock’s own history. Changes in growth, financial risk and the business can change the multiple investors pay. P/E uses earnings and P/S uses revenue from the previous twelve months.